An Open-Label Study to Evaluate Retreatment With LIPO-202

Trial Profile

An Open-Label Study to Evaluate Retreatment With LIPO-202

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Salmeterol (Primary)
  • Indications Subcutaneous fat disorders
  • Focus Adverse reactions; Registrational
  • Sponsors Neothetics
  • Most Recent Events

    • 12 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by
    • 26 Mar 2015 According to a media release, Neothetics conducted an end-of-PhaseII meeting with the U.S. FDA in order to establish LIPO-202 phase III development program.
    • 25 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top